23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human
genetics and biopharmaceutical company, today released a new report
as part of the 23andMe+ subscription service on the genetics of
panic attacks, or episodes of intense anxiety with symptoms that
include hyperventilation and a racing heart. Panic attacks may
occur as part of panic disorder or as a symptom of other anxiety
disorders, such as generalized anxiety disorder, post-traumatic
stress disorder (PTSD) or other mental health issues.
The Panic Attacks Report, powered by 23andMe Research, adds to
the collection of reports in the 23andMe service that focus on
mental health, including reports also powered by 23andMe Research
on depression and anxiety.
In addition, the unmatched size and scale of 23andMe’s database
offers a unique opportunity to estimate the likelihood of
developing a condition using polygenic risk scores (PRS). This
gives 23andMe+ members easy-to-understand insights into their
genetic risk for mental health conditions, panic attacks,
depression, or anxiety, as well as other health conditions like
high blood pressure, or coronary artery disease. Currently 23andMe
offers its subscribers more than 30 reports based on PRS. The
company has published a detailed white paper outlining the methods
used to create PRS.
Beyond offering deeper insights into the role genetics plays in
its customers’ mental health, 23andMe hopes that offering this new
report may help diminish the stigma around mental health.
"Because there’s still stigma surrounding this topic, struggling
with your mental health can be isolating, but being able to talk
about it can be really powerful,” said Becca Krock, a Senior
Product Scientist at 23andMe. "With our genetic reports, like the
Panic Attacks Report, people can access information about the
genetic component of their mental health, and get a sense of how
that fits in with their life experiences. We hope this information
can equip people to reach out and find new ways to care for their
well-being."
Panic attacks are caused when an individual’s “fight-or-flight”
response is activated, even when there is no clear, immediate
danger. They are quite common, affecting an estimated 1 in 3 people
in their lifetime, according to researchers at Harvard. In some
cases, if panic attacks occur more frequently and continue over
time, they may be diagnosed as panic disorder, a type of anxiety
disorder where panic attacks happen frequently.
As with many mood and anxiety disorders, panic attacks and panic
disorder are sometimes misdiagnosed or simply difficult to
diagnose. Understanding one’s genetic risk for these conditions,
and sharing that information with your healthcare provider may help
in reaching the right diagnosis and treatment.
23andMe’s Panic Attacks Report is powered by data from people
who have consented to participate in 23andMe Research. The report
uses machine learning techniques to estimate an individual’s
likelihood of having panic attacks.
The estimate is made using a statistical model that includes
more than 6,700 genetic markers, as well as information on an
individual’s ethnicity and birth sex. You can learn more about the
science and methodology behind our polygenic reports in this white
paper.
23andMe’s genetic health report on panic attacks can provide
customers with helpful information on their estimated genetic
likelihood of being diagnosed with the condition, but it is not a
substitute for clinical diagnosis and treatment.
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit www.23andMe.com.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s products, strategy, financial position, funding for
continued operations, cash reserves, projected costs, plans, and
objectives of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
ContactsInvestor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024